Long Term Prognostic Utility of Non-obstructive Coronary Artery Disease on CCTA in Diabetics: Results from the International Confirm Registry

Wednesday, 3:30 - 3:40 PM
Location: S502AB

PARTICIPANTS:

Philipp Blanke MD (Presenter): Nothing to Disclose
Bruce Precious MD: Nothing to Disclose
Sasi R Ganga Raju MBChB: Nothing to Disclose
Iksung Cho: Nothing to Disclose
Hyuk-Jae Chang: Nothing to Disclose
Jonathon A Leipsic MD: Speakers Bureau, General Electric Company Speakers Bureau, Edwards Lifesciences Corporation Consultant, Heartflow, Inc Consultant, Circle
Cardiovascular Imaging Inc
Fay Lin: Nothing to Disclose
Stephan Achenbach MD: Research Grant, Siemens AG Research Grant, Bayer AG Research Grant, Abbott Laboratories Speaker, Guerbet SA Speaker, Siemens AG Speaker, Bayer AG Speaker, AstraZeneca PLC Speaker, Berlin-Chemie AG Speaker, Abbott Laboratories Speaker, Edwards Lifesciences Corporation
Daniel S Berman MD: Research Grant, Lantheus Medical Imaging, Inc Research Grant, Astellas Group Research Grant, Siemens AG Speaker, Bristol-Myers Squibb Company Speaker, Covidien AG Speaker, Astellas Group Stockholder, Spectrum Dynamics Ltd Consultant, Bracco Group Consultant, FlouroPharma, Inc
Matthew J Budoff MD: Research Consultant, General Electric Company Tracy Q Callister MD: Nothing to Disclose
Mouaz Al-Mallah: Consultant, General Electric Company
Kavitha M Chinnaiyan: Nothing to Disclose
Allison Dunning: Nothing to Disclose
Augustin Delage: Nothing to Disclose
Martin Hadamitzky: Nothing to Disclose
Jorg Hausleiter: Nothing to Disclose
Leslee Shaw PhD: Grant, Bracco Group Grant, Astellas Group
Philipp A Kaufmann MD: Researcher, General Electric Company
Ricardo C Cury MD: Research Grant, Astellas Group Research Consultant, Astellas Group Research Grant, General Electric Company Research Consultant, Novartis AG Research Consultant, Heartflow, Inc
Gudrun Feuchtner MD: Nothing to Disclose
Yong-Jin Kim: Nothing to Disclose
Gilbert Raff MD: Research Grant, Siemens AG
Gianluca Pontone MD: Speakers Bureau, General Electric Company Consultant, General Electric Company Research Consultant, HeartFlow, Inc Speakers Bureau, HeartFlow, Inc Speakers Bureau, Medtronic, Inc Speakers Bureau, Bayer AG
Daniele Andreini MD: Consultant, General Electric Company Hugo M Marques MD: Nothing to Disclose
Ronan Rubinshteln MD: Fellowship funded, Koninklijke Philips NV
Millie Gomez: Nothing to Disclose
James K Min: Speakers Bureau, General Electric Company Advisory Board, General
PURPOSE

In diabetic patients the presence of non-obstructive CAD has been shown to confer a lower risk of MACE and death than obstructive disease through 2 year follow up. The relative long term prognostic value of non-obstructive disease on CCTA in diabetics is however not known.

METHOD AND MATERIALS

From 16 centers, 1823 diabetic patients undergoing CCTA without prior CAD were identified. CAD by CCTA was defined as none (0% stenosis), mild (1% to 49% stenosis) and obstructive (≥50% stenosis severity.). CAD severity was judged on a per-patient, per-vessel, and per-segment basis. Time to death, and in a subgroup, time to major adverse cardiovascular event (MACE) defined as death, myocardial infarction, unstable angina, or late coronary revascularization were both estimated using multivariable Cox proportional hazards models.

RESULTS

The median age was 61.7±11.2, 54.1% male. At a 5.2±1.6-year follow-up, 246 (13.5%) deaths occurred. In risk-adjusted analysis, both per-patient obstructive (hazard ratio [HR]: 2.1; 95% CI: 1.4-3.2; p<0.001) and non-obstructive (HR: 2.0; 95% CI: 1.3-3.1; p=0.003) CAD were related to Death. Non obstructive disease conferred a similar elevated mortality risk to single vessel obstructive disease (p=0.42). The absence of CAD by CCTA was associated with a low rate of incident mortality (annualized mortality rate: 1.2% (95% CI: 0.8-1.7%). MACE was frequent through 5 years and occurred in 295/973 (30.3%) patients. Regarding MACE, both per-patient obstructive (HR: 10.4; 95% CI: 5.9-18.1; p<0.001) and non-obstructive (HR: 4.9; 95% CI: 2.8-8.6; p<0.001) CAD were related to MACE.

CONCLUSION

Among diabetic individuals, non-obstructive and obstructive CAD by CCTA are associated with higher rates of all-cause mortality and MACE when followed to 5 years. Importantly, the relative risk of non-obstructive disease is comparable to single vessel obstructive disease.

CLINICAL RELEVANCE/APPLICATION

Coronary computed tomographic angiography in diabetics can be used for long term prognostication with respect to mortality and major adverse cardiovascular events.